NCT06132126View on ClinicalTrials.gov

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions

HealthyType 2 Diabetes Mellitus

Interventions

DRUG

LY3938577

Administered SC.

DRUG

Placebo

Administered SC.

DRUG

Insulin degludec

Administered SC.

Trial Locations (3)

33143

Qps-Mra, Llc, Miami

75247

Labcorp CRU, Dallas

92801

CenExel ACT, Anaheim

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06132126 - A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter